S. Suresh

Reply to the letter "thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy is a promising feasible therapeutic approach for myocardial infarction".

N. Maulik, M. Thirunavukkarasu, V. Selvaraju, 2016, International journal of cardiology.

Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium.

D. Mcfadden, N. Maulik, M. Thirunavukkarasu, 2015, International journal of cardiology.

Young donors with severe acute kidney injury offer an opportunity to expand the donor pool.

L. Kamal, E. Akalin, S. Greenstein, 2019, American journal of surgery.

Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease – an overview

Gautam Maulik, N. Maulik, G. Maulik, 2012, Toxicology mechanisms and methods.

A Retrospective Study of the Role of Perioperative Serum Albumin and the Albumin–Bilirubin Grade in Predicting Post-Liver Transplant Length of Stay

S. DeMaria, Hung-mo Lin, D. Katz, 2022, Seminars in cardiothoracic and vascular anesthesia.

Thioredoxin-1 (Trx-1) engineered mesenchymal stem cell therapy increased proangiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium

D. Mcfadden, N. Maulik, M. Thirunavukkarasu, 2013 .

Do laparoscopic colectomy techniques compromise oncologic principles?

L. Panait, P. Braich, S. Dudrick, 2011, Chirurgia.